This week, ASPHALION experts Enrique Gutierrez and Marta Rayo Lunar have participated in the 42-month follow-up meeting of the Horizon 2020 Tumor-LN-oC project, which was held online.
This EU-funded project is pioneering a groundbreaking approach to cancer research. The project aims to develop and validate a TRL 5 tumor-lymph node-on-chip platform. This cutting-edge technology integrates 3D tissue models with microfluidic chips, connecting surgically removed human primary tumors and lymph node (LN) tissue from the same lung cancer patients. Acting as a “biological twin” for individual patients, this platform enables the study of tumor-LN interactions, opening new possibilities for personalized medicine.
As the regulatory affairs partner, ASPHALION shared insights on the regulatory framework of this transformative technology during the meeting and outlined upcoming plans to further explore its potential.
For more information about the Tumor-LN-oC project, visit the official website: https://tumor-ln-oc.eu/.
Are you working on an EU-funded project? Let’s collaborate! Contact us at [email protected].
